Home > Boards > US Listed > Medical - Healthcare > Catalyst Biosciences (CBIO)

VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TFMG Member Profile
Member Level 
Followed By 58
Posts 2,228
Boards Moderated 4
Alias Born 04/28/19
160x600 placeholder
Catalyst Biosciences to Participate in Two Upcoming Investor Conferences GlobeNewswire Inc. - 6/10/2021 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/20/2021 4:40:26 PM
Catalyst starts dosing in early-stage MarzAA trial Seeking Alpha - 5/18/2021 8:20:20 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/18/2021 8:06:16 AM
Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, ... GlobeNewswire Inc. - 5/18/2021 8:00:00 AM
Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit GlobeNewswire Inc. - 5/13/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2021 1:02:06 PM
Catalyst Biosciences EPS misses by $0.12, beats on revenue Seeking Alpha - 5/6/2021 8:47:19 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 8:08:49 AM
Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update GlobeNewswire Inc. - 5/6/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2021 8:06:51 AM
Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hem... GlobeNewswire Inc. - 5/5/2021 8:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/4/2021 6:07:08 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/27/2021 4:31:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/27/2021 4:26:23 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 4/26/2021 5:40:27 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 4/26/2021 5:39:32 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 4/26/2021 5:38:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:29:15 PM
2 “Strong Buy” Penny Stocks That Could Deliver Massive Returns TipRanks - 4/21/2021 11:43:11 AM
Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the America... GlobeNewswire Inc. - 4/19/2021 8:00:00 AM
Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders GlobeNewswire Inc. - 4/12/2021 8:00:00 AM
Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire Inc. - 4/7/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/7/2021 10:56:35 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/5/2021 1:42:01 PM
TFMG Member Level  Tuesday, 07/09/19 03:00:43 PM
Re: None
Post # of 470 
VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA

CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia. Dr . Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator on the MarzAA Phase 2 study, will deliver an oral presentation on the final data from the Company's next-generation engineered subcutaneous ( SQ ) coagulation Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) Phase 2 trial for the treatment of hemophilia A or B with inhibitors. Additionally, the Company will have three posters covering (1) quality of life improvements for subjects in the Phase 2 MarzAA trial, (2) in silico and in vitro immunogenicity risk assessment of its next-generation engineered SQ coagulation Factor IX (FIX), dalcinonacog alfa (DalcA) compared with wildtype FIX and (3) the ongoing Phase 2b study of DalcA.
COMPANY PROFILE

COMPANY PROFILE
Catalyst Biosciences , Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.



Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!

IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences